VoCare Multi-Diagnostic Device

[mnholdem]

VoCare Develops the World's First Mobile Professional Grade Medical Multi-Diagnostic Device, Which Provides a Revolutionary Integrated Mobile Point-of-Care Solution as Well as a Remote Patient Monitoring Solution

Published: Feb 23, 2018

INDIANAPOLIS, Feb. 23, 2018 /PRNewswire/ -- VoCare, Inc., an Indiana-based company, has developed the world's first professional grade medical diagnostic device which collects 6 different health vitals and is equipped with WiFi, Bluetooth, 4G LTE for data transmission, without the need for separate peripherals or an external hub. The Vitals360 device, comparable in size to an iPhone, is the first and only telehealth solution that can be used for both Point-of-Care and Remote Patient Monitoring. The VoCare platform leverages one connected device to empower management of multiple chronic conditions such as diabetes, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), and hypertension. The Vitals360 device provides the following vital measurements: (1) Blood Glucose, (2) Blood Pressure, (3) Pulse, (4) Oximetry, (5) Temperature, and (6) Electrocardiography (ECG).

The VoCare Vitals360 runs on Android OS powered by Qualcomm chipsets, allowing the device to be used with virtually any wireless carrier worldwide such as AT&T, Verizon, T-Mobile, Sprint, Rogers, and Vodafone. Moreover, the Vitals360 can be utilized with numerous backend solutions. Steven R. Peabody, CEO of VoCare states, "We are looking forward to helping providers reduce healthcare costs as well as ensuring better outcomes for their exploding chronically ill patient population."

GEMMS, of Harris Computer Systems www.harriscomputer.com/, a division of Constellation Software, Inc., recognizes that the Vitals360 will enable healthcare professionals to meet the requirements of the Centers for Medicare and Medicaid Services (CMS) Transitional Care and Chronic Care management programs, as well as to be positioned for the use of electronic information and mobile technologies to support remote clinical healthcare and other healthcare delivery functions as proposed in the Chronic Care Act.

GEMMS will debut the Vitals360 solution at the Healthcare Information and Management Systems (HIMMS) conference in March 2018

Ben H. Park, MD, CEO of American Health Network states, "I am excited not only by the robust capability but even more so by how easy this product is to deploy. I can literally hand one to a patient in the office and that day they can be transmitting me the things I need to help manage common chronic conditions."

Todd Stallings, Vice President for Home Services Unlimited, an Indiana-based home healthcare company, states, "The VoCare solution's versatility as a point-of-care device or as a remote patient monitoring solution is a disrupting force in the home healthcare market."

VoCare is in the process of obtaining its CE mark and FDA 510k Clearance and is on track for U.S. sales in the coming months.

Source: www.prnewswire.com/news-releases/vocare-develops-the-worlds-first-mobile-professional-grade-medical-multi-diagnostic-device-which-provides-a-revolutionary-integrated-mobile-point-of-care-solution-as-well-as-a-remote-patient-monitoring-solution-300602664.html

 

[mnholdem]

The article above mentions the Chronic Care Act.  Here is some further information:

S. 870: Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017

Sponsor: 

Orrin Hatch - Senior Senator for Utah. Republican.

Introduced:

Apr 6, 2017
Status:
Enacted Via Other Measures - Provisions of this bill were incorporated into other bills which were enacted, so there will not likely be further activity on this bill.

This bill was incorporated into:
H.R. 1892: Further Extension of Continuing Appropriations Act, 2018; Department of Defense Appropriations Act, 2018; SUSTAIN Care Act of 2018; Honoring Hometown Heroes Act

Enacted:

Signed by the President on Feb 9, 2018.

Prognosis:
22% chance of being enacted according to Skopos Labs.

Excerpts from Summary:

(Sec. 101) This bill extends and expands the Independence at Home demonstration program, through which comprehensive primary care services are delivered at home to Medicare beneficiaries with multiple chronic conditions.

(Sec. 201) Current law allows a Medicare Advantage (MA) plan, until 2019, to restrict plan enrollment to individuals who are within one or more classes of special-needs individuals. The bill allows an MA plan to do so permanently, provided that the plan meets specified applicable requirements.

(Sec. 301) The Center for Medicare & Medicaid Innovation shall expand testing of an MA value-based insurance model that allows MA plans to propose and design benefit structures that vary benefits, cost-sharing, and supplemental benefits with respect to enrollees who have specific chronic diseases. The test model (initially being carried out in specified states) shall be expanded to all states, and may not be terminated prior to 2022.

(Sec. 302) Beginning in plan year 2020, an MA plan may provide certain supplemental benefits to chronically ill enrollees.

(Sec. 303) Beginning in plan year 2020, an MA plan may provide certain additional telehealth benefits.

Source: www.govtrack.us/congress/bills/115/s870

[centralcoastinvestor]

What is always reassuring to me is that while there is almost an “arms race” for medical sensing devices is the fact that there is only one best in class (actually only in class) Afrezza to handle meal time insulin.

[dreamboatcruise]

Feb 24, 2018 10:58:16 GMT -5 centralcoastinvestor said:

What is always reassuring to me is that while there is almost an “arms race” for medical sensing devices is the fact that there is only one best in class (actually only in class) Afrezza to handle meal time insulin.

What's a bit worrying is that was true when it was approved by the FDA and yet in the ensuing years the sales have been almost non existent compared to the entire prandial market.  Hopefully the barriers are being removed.